Phase 1/2, Open Label & Randomized Placebo Controlled Study to Assess the Feasibility of BGC101 (EnEPC) in the Treatment of Peripheral Arterial Disease (PAD) With Critical Limb Ischemia (CLI)

Trial Profile

Phase 1/2, Open Label & Randomized Placebo Controlled Study to Assess the Feasibility of BGC101 (EnEPC) in the Treatment of Peripheral Arterial Disease (PAD) With Critical Limb Ischemia (CLI)

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 05 Oct 2017

At a glance

  • Drugs BGC-101-BioGenCell (Primary)
  • Indications Peripheral arterial occlusive disorders; Peripheral vascular disorders
  • Focus Adverse reactions; First in man
  • Sponsors BioGenCell
  • Most Recent Events

    • 05 Oct 2017 New trial record
    • 15 Sep 2017 Preliminary safety results (n=5) presented at the 53rd Annual Meeting of the European Association for the Study of Diabetes
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top